Literature DB >> 24415352

Primary PCI in dabigatran-treated patient: is transradial approach and bivalirudin infusion a safe and effective therapeutic option?

Francesco Summaria1, Enrico Romagnoli, Marina Mustilli, Roberto Patrizi, Adolfo Pagnanelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24415352     DOI： 10.1007/s11739-013-1037-4

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  7 in total

1.  Acute management of ST-elevation myocardial infarction patients taking dabigatran.

Authors:  Jay Shavadia; Robert C Welsh
Journal:  Can J Cardiol       Date:  2013-09-08       Impact factor: 5.223

2.  Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.

Authors:  Willem J M Dewilde; Tom Oirbans; Freek W A Verheugt; Johannes C Kelder; Bart J G L De Smet; Jean-Paul Herrman; Tom Adriaenssens; Mathias Vrolix; Antonius A C M Heestermans; Marije M Vis; Jan G P Tijsen; Arnoud W van 't Hof; Jurriën M ten Berg
Journal:  Lancet       Date:  2013-02-13       Impact factor: 79.321

3.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

Authors:  S R Mehta; S Yusuf; R J Peters; M E Bertrand; B S Lewis; M K Natarajan; K Malmberg; H Rupprecht; F Zhao; S Chrolavicius; I Copland; K A Fox
Journal:  Lancet       Date:  2001-08-18       Impact factor: 79.321

4.  Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors.

Authors:  Ramin Artang; Eric Rome; Jørn Dalsgaard Nielsen; Humberto J Vidaillet
Journal:  Am J Cardiol       Date:  2013-09-25       Impact factor: 2.778

5.  Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).

Authors:  Marco Valgimigli; Marco Borghesi; Matteo Tebaldi; Pascal Vranckx; Giovanni Parrinello; Roberto Ferrari
Journal:  Eur Heart J       Date:  2013-01-12       Impact factor: 29.983

6.  A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients.

Authors:  Pascal Vranckx; Freek W A Verheugt; Moniek P de Maat; Victor A W M Ulmans; Evelyn Regar; Peter Smits; Jurrien M ten Berg; Wietze Lindeboom; Russel L Jones; Jeffrey Friedman; Paul Reilly; Frank W G Leebeek
Journal:  EuroIntervention       Date:  2013-01-22       Impact factor: 6.534

Review 7.  Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.

Authors:  Andreas Clemens; Mandy Fraessdorf; Jeffrey Friedman
Journal:  Vasc Health Risk Manag       Date:  2013-10-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.